| Ytd | -4.15% | |
| 1y | -30.15% |
| Open | 49.02 | Prev Close | 47.94 | Low | 48.61 | High | 49.55 | Mkt Cap | 215.85B |
| Vol | 11.03M | Avg Vol | 14.91M | EPS | 4.16 | P/E | 11.72 | Forward P/E | 14.85 |
| Beta | 0.35 | Short Ratio | 1.84 | Inst. Own | 9.81% | Dividend | 1.80 | Div Yield | 3.73 |
| Ex Div Date | 03-30 | Earning | 08-05 | 50-d Avg | 44.26 | 200-d Avg | 47.86 | 1yr Est | 47.53 |
NVO News
In the latest trading session, Novo Nordisk (NVO) closed at $48.77, marking a +1.73% move from the p
Medicare's new GLP-1 coverage could expand access to weight-loss drugs, making ETFs a diversified wa
Artificial intelligence is reshaping nearly every industry, but some of its biggest opportunities ar
Medicare GLP-1 coverage starts Wednesday. Here’s what patients should know about cost, eligibility a
Starting Wednesday, eligible seniors with Medicare coverage can access GLP-1s for obesity with a cop
NVO and VKTX stocks offer contrasting opportunities in the fast-growing obesity market, with key dif
Recently, Zacks.com users have been paying close attention to Novo Nordisk (NVO). This makes it wort
Citi has said Novo Nordisk's (NYSE:NVO) Wegovy pill is outpacing its rivals in the United States, ev
I present my top 10 high-yield dividend stocks for July 2026, emphasizing margin of safety, attracti
Millions of older Americans in Medicare are about to gain access to obesity drugs through Medicare's
This whale alert can help traders discover the next big trading opportunities. Whales are entities w
Novo Nordisk is no longer the front-runner, but it's not out of the running, either.
The Medicare GLP-1 Bridge program will be the first time eligible Medicare Part D patients will be a
Denmark's Novo Nordisk , the maker of weight-loss drug Wegovy, hopes insurance will cover more U.S.
White House denies reports Trump received Eli Lilly's unapproved obesity drug retatrutide throug
Novo-Nordisk shares are trading higher by more than 6% on Monday as GLP‑1 support initiatives aimed
As demand for GLP-1 medications continues to increase across the U.S., CVS Health® (NYSE:CVS) today
As millions take GLP-1 drugs, packaged food giants face declining volumes while protein brands and s
Hims & Hers Health (NYSE: HIMS) shares are climbing after Barclays reiterated its bullish stance
Novo Nordisk investigates claims by cyber group FulcrumSec alleging a 1.3TB data theft after a faile
https://www.reuters.com/legal/government/hacking-group-claims-major-hack-novo-nordisk-attempted-25-m
https://www.reuters.com/world/novo-nordisk-seek-regulatory-approval-wegovy-pill-china-soon-says-ceo-
Medicare's GLP-1 rollout could overwhelm doctors as seniors rush for $50 weight-loss drugs.
Novo Nordisk wins U.K. approval for Wegovy pill, offering adults a daily oral weight-loss option bac
https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-detai
https://ml-eu.globenewswire.com/Resource/Download/eb763000-5b1f-4433-9713-f86ae3f76643
Novo Nordisk reported positive diabetes and weight-loss data, advanced zenagamtide plans, and topped
Novo Nordisk exploring additional uses for obesity drug semaglutide, including potential for longevi
https://www.sec.gov/ix?doc=/Archives/edgar/data/863894/000143774926019478/veru20260601_8k.htm
